Sirtex develops interventional medical products using small-particle technology that consists of biocompatible resin spheres containing a radioactive isotope, which are delivered by selective internal radiation therapy (SIRT) to the liver to treat liver cancer. The company's lead product is SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy for liver cancer that has been supplied to over 1,300 medical centers in more than 50 countries. Sirtex is committed to serving its medical customers and creating a collaborative working culture to introduce innovative new therapies that promise to improve the lives of people around the world facing the challenges of cancer.